Biomarkers for ALK and ROS1 in lung cancer: Immunohistochemistry and fluorescent in situ hybridization
from Archives of Pathology & Laboratory Medicine
A small proportion of non–small cell lung cancers harbor rearrangements of ALK or ROS1 genes, and these tumors are sensitive to targeted tyrosine kinase inhibitors. It is crucial for pathologists to accurately identify tumors with these genetic alterations to enable patients to access optimal treatments and avoid unnecessary side effects of less effective agents. Although a number of different techniques can be used to identify ALK- and ROS1-rearranged lung cancers, immunohistochemistry and fluorescence in situ hybridization are the mainstays.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063